Royce & Associates LP Raises Stake in AngioDynamics, Inc. $ANGO

Royce & Associates LP raised its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 27.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,267,451 shares of the medical instruments supplier’s stock after purchasing an additional 272,091 shares during the quarter. Royce & Associates LP owned 3.07% of AngioDynamics worth $16,274,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. State of Alaska Department of Revenue purchased a new position in AngioDynamics during the third quarter valued at approximately $25,000. Farther Finance Advisors LLC lifted its holdings in AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 1,199 shares in the last quarter. Washington Trust Advisors Inc. purchased a new position in AngioDynamics during the third quarter valued at approximately $27,000. State of Wyoming purchased a new position in AngioDynamics during the second quarter valued at approximately $31,000. Finally, Russell Investments Group Ltd. lifted its holdings in AngioDynamics by 329.5% during the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 3,213 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Wall Street Analysts Forecast Growth

ANGO has been the topic of several analyst reports. Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Canaccord Genuity Group lowered their price target on shares of AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Monday, April 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. Finally, Zacks Research downgraded shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.67.

AngioDynamics Stock Performance

ANGO stock opened at $11.80 on Wednesday. AngioDynamics, Inc. has a one year low of $8.36 and a one year high of $13.99. The company’s fifty day moving average price is $10.87 and its 200-day moving average price is $11.41. The company has a market capitalization of $487.58 million, a PE ratio of -15.73 and a beta of 0.37.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, April 2nd. The medical instruments supplier reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. The firm had revenue of $78.42 million for the quarter, compared to the consensus estimate of $76.77 million. On average, research analysts predict that AngioDynamics, Inc. will post -0.19 EPS for the current fiscal year.

AngioDynamics Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.